Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Franklin Templeton's Alternatives Push Is Turning Into Organic Growth, UBS Says

Franklin Templeton's Alternatives Push Is Turning Into Organic Growth, UBS Says

MT newswireMT newswire2026/10/07 16:59

12:59 PM EDT, 10/07/2026 (MT Newswires) -- Franklin Templeton's (BEN) years of investment in alternatives, separately managed accounts and active exchange-traded funds are starting to deliver organic growth and wider margins, which should support more durable earnings, UBS said in a note emailed Wednesday. The bank said the asset manager is on track for positive organic growth in fiscal 2026 for the first time in over a decade, with private markets strength offsetting legacy active outflows. UBS also expects operating margins to keep expanding, supported by expense discipline, operating leverage and a growing contribution from higher-margin private assets. The bank assumed coverage on the stock with a buy rating and $40 per share price target. Price: 32.50, Change: +0.05, Percent Change: +0.17

12:59 PM EDT, 10/07/2026 (MT Newswires) -- Franklin Templeton's (BEN) years of investment in alternatives, separately managed accounts and active exchange-traded funds are starting to deliver organic growth and wider margins, which should support more durable earnings, UBS said in a note emailed Wednesday. The bank said the asset manager is on track for positive organic growth in fiscal 2026 for the first time in over a decade, with private markets strength offsetting legacy active outflows. UBS also expects operating margins to keep expanding, supported by expense discipline, operating leverage and a growing contribution from higher-margin private assets. The bank assumed coverage on the stock with a buy rating and $40 per share price target. Price: 32.50, Change: +0.05, Percent Change: +0.17
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53

Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million

Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).

智通财经•2026/11/06 07:50